Article Excerpt: The opioid crisis, whilst predominantly associated with the United States, has become a growing global health issue. In the wake of this epidemic, drug developers have been searching tirelessly for non-addictive medicines that can combat pain without triggering the brain’s reward systems that contribute to the risk of addiction.
Recent success has seen the US Food and Drug Administration (FDA) announce the approval of Journavx™ (suzetrigine), the first new class of pain management medicine to be approved in the US since 1998. Further breakthroughs in non-addictive pain medications may come in the form of therapeutics that utilize a nanoparticle delivery system.
Full Article: https://tinyurl.com/y42jsxy2
Article Source: Technology Networks